Modeling and simulation is proposed to support drug development phase transitions in oncology. Longitudinal tumor-size data recorded in patients are modeled to inform treatment efficacy, and the tumor growth inhibition (TGI) metrics are related to clinical end points, e.g., overall survival.
August 1, 2014
Author(s): Laurent Claret, Rene Bruno
Year: August 1, 2014